Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online May 31, 2016.
Article Versions
- previous version (March 28, 2016 - 17:56).
- You are viewing the most recent version of this article.
Copyright & Usage
© PDA, Inc. 2016
Author Information
- John Mattila1,*,
- Mike Clark2,
- Shengjiang Liu3,
- John Pieracci4,
- Thomas R. Gervais5,
- Eileen Wilson6,
- Olga Galperina7,
- Xinfang Li8,
- David Roush9,
- Konstantin Zoeller10,
- Helene Brough11 and
- Christelle Simpson-Platre12
- 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY;
- 2AbbVie, Inc., Worcester, MA;
- 3Bayer Corporation, Berkeley, CA;
- 4Biogen, Cambridge, MA;
- 5Bristol-Myers Squibb, East Syracuse, NY;
- 6GlaxoSmithKline plc, King of Prussia, PA;
- 7GlaxoSmithKline plc, Rockville, MD;
- 8ImmunoGen, Inc., Waltham, MA;
- 9Merck, Sharp and Dohme, Inc., Kenilworth, NJ;
- 10Novartis Pharma AG, Basel, Switzerland;
- 11Shire plc., Pepperell, MA; and
- 12Biophorum Operations Group, Sheffield, UK
- ↵* Corresponding Author: John Mattila, Regeneron Pharmaceuticals, Inc., Tarrytown, NY; e-mail: John.Mattila{at}regeneron.com
Cited By...
Jump to section
Related Articles
Cited By...
- Using Sensitivity Analysis to Simplify the Virus Safety Factor Calculation in the Manufacture of Biopharmaceuticals
- Proceedings of the 2019 Viral Clearance Symposium, Session 4: Viral Clearance Strategy and Process Understanding
- Proceedings of the 2019 Viral Clearance Symposium, Session 1: Viral Clearance Strategies and Case Studies
- Proceedings of the 2019 Viral Clearance Symposium, Session 6: Virus-Retentive Filtration
- Twenty plus Years of Data Demonstrating Virus Filtration as an Effective and Robust Step for Large Virus Removal
- Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants
- The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim
- Proceedings of the 2017 Viral Clearance Symposium, Session 1.2: Upstream Mitigation, Part 2--Virus Barrier Filter and HTST